Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase in Patients With Cystic Fibrosis Previously Treated With Pulmozyme

Next Previous
Trial Profile

A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase in Patients With Cystic Fibrosis Previously Treated With Pulmozyme

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alidornase alfa (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Protalix Biotherapeutics

Most Recent Events

  • 07 Jun 2017 Results published in a Protalix Biosciences media release.
  • 07 Jun 2017 According to a Protalix Biotherapeutics media release, new clinical data from this trial will be presented at the 40th European Cystic Fibrosis Society Conference.
  • 23 May 2017 Status changed from active, no longer recruiting to completed. as reported in a Protalix Biotherapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top